StoxOnesource Specialty Pharma vs Syngene International: share price & financials comparison
NSE: ONESOURCE vs SYNGENE · Healthcare · as of 06 Nov 2026
Both prices rebased to 100 at the start of the selected period.
Onesource Specialty Pharma vs Syngene International at a glance
Onesource Specialty Pharma (ONESOURCE) has a market capitalisation of ₹18,345 Cr, against ₹16,846 Cr for Syngene International (SYNGENE). Over the past year Onesource Specialty Pharma has returned -13.7%, compared with -36.7% for Syngene International. Syngene International earns a higher return on equity (0.8% vs -0.0%). Onesource Specialty Pharma comes out ahead on valuation, growth, momentum and technicals. Syngene International comes out ahead on size, profitability and financial health. Across the scored metrics below, Onesource Specialty Pharma leads on 6 and Syngene International on 5. On StoxGud's 10-point checklist, Onesource Specialty Pharma scores 4/10 and Syngene International scores 3/10.
| Metric | Onesource Specialty Pharma | Syngene International |
|---|---|---|
| Size | ||
| Market cap | ₹18,345 Cr | ₹16,846 Cr |
| Revenue (latest FY) | ₹1,422 Cr | ₹3,739 Cr |
| Net profit (latest FY) | ₹-74 Cr | ₹0 Cr |
| Valuation | ||
| P/E | — | 441.0 |
| P/B | 3.10 | 3.47 |
| Dividend yield | — | 0.30% |
| Profitability | ||
| Return on equity | 0.0% | 0.8% |
| Net profit margin | -0.1% | 1.1% |
| Operating margin | 23.5% | 21.3% |
| Growth | ||
| Revenue growth (YoY) | +37.4% | -8.6% |
| Net profit growth (YoY) | +687.0% | — |
| Revenue CAGR (multi-year) | — | +11.3% |
| Financial health | ||
| Debt to equity | 0.25 | 0.01 |
| Momentum | ||
| 1-month return | +4.7% | +15.8% |
| 1-year return | -13.7% | -36.7% |
| 3-year CAGR | — | -16.4% |
| 5-year CAGR | — | -5.3% |
| 10-year CAGR | — | +4.3% |
| Distance from 52W high | -14.8% | -37.1% |
| Technicals | ||
| RSI (14) | 71 | 60 |
| Price vs 200-day avg | +3.2% | -1.8% |
Highlighted cells lead on that metric. Market cap, revenue and RSI are shown for context and not scored.
10-point checklist side by side
| Check | Onesource Specialty Pharma | Syngene International |
|---|---|---|
| Price above 50-day average | ✓ | ✓ |
| Price above 200-day average | ✓ | ✗ |
| 50-day average above 200-day (uptrend) | ✗ | ✗ |
| RSI in healthy 40–70 zone | ✗ | ✓ |
| Positive 1-year return | ✗ | ✗ |
| Return on equity above 15% | ✗ | ✗ |
| Debt to equity below 1 | ✓ | ✓ |
| Revenue growing year on year | ✓ | ✗ |
| Net profit margin above 10% | ✗ | ✗ |
| P/E below industry median | ✗ | ✗ |
| Score | 4/10 | 3/10 |
A rules-based screen for education only — not a buy or sell recommendation.
FAQs
Which is bigger, Onesource Specialty Pharma or Syngene International?
Onesource Specialty Pharma has a market cap of ₹18,345 Cr and Syngene International has a market cap of ₹16,846 Cr as of 06 Nov 2026.
Which gave better returns in the last year, Onesource Specialty Pharma or Syngene International?
Onesource Specialty Pharma did better: Onesource Specialty Pharma returned -13.7% and Syngene International returned -36.7% over one year.
Is Onesource Specialty Pharma or Syngene International a better buy?
StoxGud does not give buy or sell recommendations. On our rules-based checklist Onesource Specialty Pharma scores 4/10 and Syngene International scores 3/10; compare valuation, profitability, growth and momentum above and consult a SEBI-registered adviser.